Trials / Not Yet Recruiting
Not Yet RecruitingNCT06887933
A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer
A Prospective, Multicentre, Open Labelled, Single Arm Phase-IV Clinical Trial of Niraparib in Indian Patients With Advanced or Relapsed Ovarian Cancer Who Are in Complete or Partial Response Following Platinum Based Chemotherapy
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 67 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to learn about the safety profile of niraparib in adult female participants for the treatment of advanced or relapsed epithelial ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Niraparib | Niraparib will be administered. |
Timeline
- Start date
- 2025-04-22
- Primary completion
- 2026-03-20
- Completion
- 2026-07-08
- First posted
- 2025-03-21
- Last updated
- 2025-03-21
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06887933. Inclusion in this directory is not an endorsement.